Group 1 - The top three companies with the highest short positions are Vanke Enterprises (02202), COSCO Shipping Holdings (01919), and Heng Rui Medicine (01276), with short ratios of 18.48%, 16.79%, and 15.54% respectively [1][2] - The companies with the largest absolute increase in short positions are CATL (03750), Lens Technology (06613), and UBTECH Robotics (09880), which increased by 2.35%, 2.34%, and 1.29% respectively [1][2] - The companies with the largest absolute decrease in short positions are Changfei Optical Fiber (06869), Mao Ge Ping (01318), and Meilan Airport (00357), which decreased by -1.26%, -0.68%, and -0.67% respectively [1][2] Group 2 - The latest short ratio for Vanke Enterprises (02202) is 18.48%, down from 19.04% previously [3] - The latest short ratio for COSCO Shipping Holdings (01919) is 16.79%, down from 16.79% previously [2] - The latest short ratio for Heng Rui Medicine (01276) is 15.54%, up from 3919.30 million shares to 4011.67 million shares [2]

国泰海通证券股份有限公司 关于上海君实生物医药科技股份有限公司 募集资金投资项目延期的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐人"）作为上 海君实生物医药科技股份有限公司（以下简称"君实生物"、"公司"或"发行人"） 2022 年度向特定对象发行 A 股股票的保荐人，根据《证券发行上市保荐业务管 理办法》《上市公司募集资金监管规则》《上海证券交易所科创板股票上市规则》 《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等有关法 律法规和规范性文件的要求，就君实生物募集资金投资项目延期的事项进行了审 慎核查，并发表如下核查意见: 一、募集资金基本情况 根据中国证券监督管理委员会出具的《关于同意上海君实生物医药科技股份 有限公司向特定对象发行股票注册的批复》（证监许可〔2022〕2616 号），公司获 准向特定对象发行人民币普通股 7,000.00 万股，每股发行价格为人民币 53.95 元， 募集资金总额为人民币 3,776,500,000.00 元；扣除各项发行费用合计人民币 31,697,205.06 元（不含增值税）后，实际募集资金净额为人民币 3,744,802, ...

证券代码：688180 证券简称：君实生物 公告编号：临 2025-077 上海君实生物医药科技股份有限公司 关于募集资金投资项目延期的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海君实生物医药科技股份有限公司（以下简称"公司"）于 2025 年 12 月 29 日召开第四届董事会第十六次会议，审议通过了《关于募集资金投资项目延 期的议案》，同意将公司 2022 年度向特定对象发行 A 股股票募集资金投资项目 （以下简称"募投项目"）之"创新药研发项目"的项目实施期限延期至 2028 年 12 月及"上海君实生物科技总部及研发基地项目"的项目实施期限延期至 2026 年 6 月。本次募投项目延期仅涉及项目进度的变化，未改变募投项目的投 资内容、投资总额、实施主体等，不会对募投项目的实施造成实质性影响。保荐 人国泰海通证券股份有限公司（以下简称"保荐人"）对本事项出具了明确的核 查意见，本事项无需提交公司股东会审议。现将相关情况公告如下： 一、募集资金基本情况 根据中国证券监督管理委员会出具的《关于同意上海君实生 ...

Core Insights - JD Health and Junshi Biosciences have established a strategic partnership to enhance ecological services for oral mucositis care in cancer patients [1][2] - The collaboration aims to integrate JD Health's resources in medical services and instant retail to create a comprehensive ecosystem for oral care [1][3] Group 1: Partnership Details - The partnership focuses on a core model of "professional medical services + compliant supply + instant accessibility" [1] - The newly launched oral mucosal liquid dressing, Su Shu®, is exclusively available on JD Health, providing a full-chain solution for oral health [1][2] Group 2: Clinical Context - Clinical data indicates that 20%-40% of patients undergoing chemotherapy experience oral mucositis, with over 80% of radiotherapy patients suffering from moderate to severe pain [2] - Oral mucositis significantly impacts patients' quality of life and can lead to treatment delays, increased costs, and heightened psychological burdens [2] Group 3: Product and Service Integration - JD Health leverages its online consultation, pharmaceutical retail, and rapid delivery capabilities to create a three-in-one service system for cancer patients [1][3] - The collaboration addresses key pain points in care, such as the difficulty in obtaining compliant devices and the lack of professional guidance [1][3] Group 4: Strategic Implications - Junshi Biosciences aims to focus on comprehensive health management for cancer patients, with Su Shu® representing a strategic shift towards integrated health management [2][3] - The partnership exemplifies the integration of medical and retail resources in specialized healthcare scenarios, setting a benchmark in the medical device sector [3]

Group 1 - The company, Junshi Biosciences (01877), has received a registration notice from the China Interbank Market Dealers Association for its technology innovation bonds [1] - The registered amount for the medium-term notes is set at 2 billion RMB, with a validity period of two years from the date of the notice [1] - Shanghai Bank (601229) will act as the lead underwriter for this bond issuance [1]

Group 1 - The company, Junshi Biosciences (01877), has received a registration notice for its technology innovation bonds from the China Interbank Market Dealers Association [1] - The registered amount for the medium-term notes is set at RMB 2 billion, with a validity period of two years from the date of the notice [1] - Shanghai Bank Co., Ltd. will act as the lead underwriter for this bond issuance [1]

Investment Rating - The report maintains an "Outperform" rating for the industry [7] Core Insights - The year 2026 is expected to be a significant year for IO combined with ADC, with China leading the development of second-generation IO combined ADC therapies [5][24] - The immune therapy and ADC have a natural complementarity, enhancing efficacy and expanding the beneficiary population [17] - The report highlights the importance of innovative drugs, medical devices, and the focus on domestic demand in the pharmaceutical sector [5][48] Summary by Sections 1. IO+ADC: 2026 Catalyst Year - PD-1 combined with ADC has shown promising results in first-line NSCLC, with a global phase III trial expected to report results in 2026 [1.1][27] - Second-generation IO combined with ADC is progressing, with several global phase III studies initiated [1.2][39] 2. Weekly Market Review and Hotspot Tracking (Dec 22-26, 2025) - The CITIC Pharmaceutical Index fell by 0.2%, underperforming the CSI 300 Index by 2.1 percentage points [4][48] - The report notes a general decline in the pharmaceutical sector, with specific stocks like Hongyuan Pharmaceutical and Luyuan Pharmaceutical showing significant gains [4][63] 3. Investment Focus - The report suggests focusing on innovative drugs with commercial capabilities, potential blockbuster candidates, and cutting-edge technologies such as gene therapy and CAR-T [5][48] - Medical devices are highlighted as a sector with growth potential, particularly in areas like endoscopy and robotics [5][48]

Core Viewpoint - The company has received a registration notice from the China Interbank Market Dealers Association for its technology innovation bonds, allowing it to issue bonds worth up to 2 billion RMB [1] Group 1: Bond Registration Details - The registered bond type is medium-term notes with a total registration amount of 2 billion RMB [1] - The registration validity period is effective for 2 years from the date of the notice [1] - Shanghai Bank Co., Ltd. is the lead underwriter for the bond issuance [1] Group 2: Issuance Strategy - The company can issue the technology innovation bonds in tranches during the registration validity period [1] - The timing of the bond issuance will depend on the company's funding needs and market conditions [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 上海君實生物醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1877） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條規則作出。 茲載列上海君實生物醫藥科技股份有限公司在上海證券交易所網站刊發之《上海 君實生物醫藥科技股份有限公司關於收到中國銀行間市場交易商協會<接受註冊 通知書>的公告》，僅供參閱。 承董事會命 上海君實生物醫藥科技股份有限公司 熊俊先生 主席 中國，上海，2025年12月28日 SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海君实生物医药科技股份有限公司（以下简称"公司"）2024 年年度股东 大会审议通过了《关于发行境内外债务融资工具的一般性授权的议案》， ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* （股份代號：1877） 獲中國銀行間市場交易商協會接受註冊中期票據 本公告由上海君實生物醫藥科技股份有限公司（「本公司」）自願作出。請亦參見本 公司於2025年12月28日刊發的海外監管公告。 近日，本公司收到中國銀行間市場交易商協會（「交易商協會」）印發的《接受註冊 通知書》（中市協注[2025]MTN1249號）（「通知書」），交易商協會決定接受本公司 科技創新債券註冊。現就有關事項公告如下： 本公司將按照有關法律法規的要求及本公司股東會的授權，在規定的有效期內， 根據資金需求和市場情況擇機實施本次科技創新債券發行事宜，並按照相關規定 及時進行披露。 上海君實生物醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 1 一、本公司本次註冊基礎品種為中期票據，註冊金額為人民幣20億元，註冊額度 自本通知書落款之日 ...